Palo Alto, California 94305

  • Insulin Resistance

Purpose:

The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning. If they meet criteria, they will be asked to take either Pioglitazone or a placebo for a 90-day trial. Participants will undergo an Oral Glucose Tolerance Test to measure fasting insulin and glucose levels, as well as routine blood testing. The investigators hope to quantify the role of Pioglitazone in patients with mood disorders and compare the values to those previously obtained in a healthy age-matched control population. The investigators also hope to examine the association between IR and cognitive performance and clinical course of depression in patients with mood disorders.


Criteria:

Inclusion Criteria: - Age between 20 and 65 years - BMI between 25 and 35 - Diagnosis of unipolar, non-psychotic, non-melancholic major depressive disorder (MDD) or depressive episode of bipolar disorder (Bipolar I, II or NOS) - Depression severity as defined by score of < 12 on the 21-item Hamilton Rating Scale for Depression and no psychiatric admission within 6 months from study entry and no suicide attempt within the last 12 months - Willingness to sign human subjects consent form Exclusion Criteria: - Diagnosis of possible or probable cognitive impairment - For women only: pregnancy, breastfeeding - Personal history of Type I or Type II diabetes - Unstable cardiovascular disease or other major medical condition, or history of myocardial infarction within the previous year - Significant cerebrovascular disease, as evidenced by neurological examination, uncontrolled hypertension (systolic blood pressure > 170 or diastolic blood pressures > 100) - Current drug or alcohol abuse - History of neurological disorder, e.g. multiple sclerosis, stroke etc - Use of any drug that may significantly affect psychometric testing or the insulin testing


NCT ID:

NCT01559857


Primary Contact:

Principal Investigator
Natalie Rasgon, MD, PhD
Stanford University

Rachael Lazar
Phone: 650-724-4559
Email: rlazar@stanford.edu


Backup Contact:

N/A


Location Contact:

Palo Alto, California 94305
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.